Literature DB >> 16882598

The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.

E V Stenbøg1, B Windelborg, A Hørlyck, T Herlin.   

Abstract

In Kawasaki disease (KD), a systemic vasculitis of childhood, serum levels of proinflammatory cytokines such as tumour necrosis factor alpha (TNFalpha) are elevated during the acute phase of the disease. Although the majority of children recover completely from a single dose of intravenous immunoglobulin (IVIG), the treatment is not always effective. In refractory cases of KD there are no documented treatment guidelines. A future role of biological agents directed against proinflammatory cytokines has recently been suggested by the American Heart Association (AHA). We describe two infants with severe KD, complicated by coronary as well as extracoronary aneurysms, who responded neither to repeated treatment with IVIG plus aspirin nor to corticosteroids. The children were subsequently treated with infliximab. In both cases, the effect was prompt and long-lasting. Clinical improvement was seen within a few days after the first dose, and regression of the aneurysms occurred within weeks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882598     DOI: 10.1080/03009740600588228

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  4 in total

1.  Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Jane C Burns; Brookie M Best; Asuncion Mejias; Lynn Mahony; David E Fixler; Hasan S Jafri; Marian E Melish; Mary Anne Jackson; Basim I Asmar; David J Lang; James D Connor; Edmund V Capparelli; Monica L Keen; Khalid Mamun; Gregory F Keenan; Octavio Ramilo
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

Review 2.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

Review 3.  What's new in the aetiopathogenesis of vasculitis?

Authors:  Paul A Brogan
Journal:  Pediatr Nephrol       Date:  2007-03-15       Impact factor: 3.714

4.  Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report.

Authors:  Robert J Brogan; Despina Eleftheriou; James Gnanapragasam; Nigel J Klein; Paul A Brogan
Journal:  Pediatr Rheumatol Online J       Date:  2009-01-21       Impact factor: 3.054

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.